Mature Versus Registration Studies of Immuno‐Oncology Agents: Does Value Improve With Time? After an assessment of drivers of LOS among patients receiving HD-MTX, we identified discharge criteria as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results